Fig. 8

Pharmacological targeting of p38α inhibits β-catenin transcriptional activity in patient-derived CRC-SCs and tumor intestinal organoids. A Schematic representation of the experimental procedure used for generating patient-derived CRC-SCs and organoids (created with BioRender.com). B Quantification results of the digital droplet PCR (ddPCR) assay (copies/µL) of c-Myc mRNA expression, as processed by QuantaSoft. Patient-derived CRC-SC tumorspheres (left panel) and patient-derived CRC organoids (right panel) were treated with the GSK3β inhibitor TWS-119 (10 μM) for 4 h and subsequently treated or not with the p38α inhibitor ralimetinib (10 μM) for 24 h. The error bars represent the maximum and minimum Poisson distribution for the 95% confidence interval generated by QuantaSoft. Results are representative of at least three independent experiments